Invested in Her campaign extends fundraising deadline
The Longevity Science Foundation says the Invested in Her campaign extends its fundraising deadline to October 1, 2026. Community support is driving the push toward a $250,000 goal for early-stage research on ovarian aging and menopause, a gap that shapes women's long-term healthspan.
Key Takeaways
- The Invested in Her campaign fundraising deadline is now October 1, 2026.
- The Longevity Science Foundation is targeting $250,000 for ovarian aging and menopause research.
- Only 8.8% of NIH funding goes to women's health research, with little focused on ovarian aging.
- 100% of donations go directly to research, with no overhead deducted.
- The campaign funds measurement, biological understanding, and early-stage intervention.
What happened with the Invested in Her campaign?
According to a Lifespan.io report on a Longevity Science Foundation press release, the organization is extending the Invested in Her campaign because support from its community remains strong.
The drive aims to raise $250,000 for early-stage science on ovarian aging and the menopausal transition—areas the foundation calls among the most underfunded in medicine.
Readers following longevity and biohacking coverage will recognize why that timeline matters: women's reproductive aging research rarely gets sustained attention or capital.
Why does this fundraising extension matter for women's healthspan?
Hundreds of millions of women live longer than men yet spend more years in poor health. The foundation ties that disparity to ovarian aging and menopause biology that still lack adequate study.
Only 8.8% of NIH funding is directed to women's health research, and only a fraction of that examines ovarian aging and the menopausal transition. Limited evidence then constrains prevention, early intervention, and targeted treatment.
Hormonal changes linked to ovarian decline ripple across cardiometabolic, brain, and skeletal health. Closing the research gap, the foundation argues, is how the field begins to close the health gap.
How will Invested in Her use the funds?
Through its scientific review process, the Longevity Science Foundation says it has identified high-impact projects ready for immediate funding. The portfolio spans three coordinated pillars rather than isolated therapies alone.
Measurement work aims to improve how ovarian aging and the menopausal transition are tracked. Biology research seeks mechanisms linking reproductive aging to broader systemic decline. Intervention efforts advance early-stage approaches that treat reproductive aging as modifiable, not inevitable.
The campaign recently gathered investors, clinicians, researchers, founders, and advocates at 7 World Trade Center in New York City. Attendees flagged healthcare system design and lack of research funding as leading barriers.
Through October 1, Invested in Her will keep directing attention and capital to that agenda. Eligible gifts are tax-deductible, and the foundation states that 100% of donations go directly to research with no overhead deducted.
What barriers did campaign supporters highlight?
At the New York event, personal stories, presentations, panel discussions, and networking framed both the challenges in women's health and the openings for change. Feedback from the room reinforced that progress stalls without better system design and more research capital.
For the Longevity Science Foundation, the response is to keep funding holistic women's health research aimed at equitable solutions. Invested in Her is meant to convert that community momentum into grants that improve how reproductive aging is measured, understood, and addressed.
The extension to October 1, 2026, keeps the window open while the foundation works toward the $250,000 target. That date is the clearest near-term marker for donors and partners watching women's longevity science.